PYC Therapeutics (ASX:PYC) Moat Score: 3/10 (As of Jun. 29, 2026)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
36 GF Score
Price A$1.65
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Moat Score?

PYC Therapeutics ASX:PYC +7.49% 36 Moat Score is 3 as of Jun. 29, 2026. GuruFocus rates ASX:PYC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, PYC Therapeutics ranks better than 75.52% on this metric.

PYC Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

PYC Therapeutics has No Moat: PYC Therapeutics has some proprietary technology in biotech, but the industry is highly competitive with significant regulatory hurdles. The company lacks strong market leadership, customer loyalty, and pricing power to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PYC Therapeutics might have No Moat - Very weak/transient advantages.

PYC Therapeutics  (ASX:PYC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PYC Therapeutics Moat Score Related Terms

ASX:PYC vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, PYC Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's Moat Score falls into.


ASX:PYC
36GF Score
PYC Therapeutics Ltd ASX:PYC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
PYC Therapeutics (ASX:PYC) has a Moat Score of 3 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PYC Therapeutics ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is PYC Therapeutics' Moat Score too high?
PYC Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. PYC Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, PYC Therapeutics ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PYC Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #343 out of 1401 companies for Moat Score. This places PYC Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. PYC Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PYC Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PYC Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. PYC Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Moat Score is 3 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
36GF Score

Get the complete analysis for ASX:PYC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.65
Price